US20080306118A1 - Process for the crystallization of (R) - or (S) - Lansoprazole - Google Patents

Process for the crystallization of (R) - or (S) - Lansoprazole Download PDF

Info

Publication number
US20080306118A1
US20080306118A1 US11/899,918 US89991807A US2008306118A1 US 20080306118 A1 US20080306118 A1 US 20080306118A1 US 89991807 A US89991807 A US 89991807A US 2008306118 A1 US2008306118 A1 US 2008306118A1
Authority
US
United States
Prior art keywords
crystal
methyl
lansoprazole
benzimidazole
trifluoroethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/899,918
Other languages
English (en)
Inventor
Hideo Hashimoto
Tadashi Urai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18838123&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20080306118(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Priority to US11/899,918 priority Critical patent/US20080306118A1/en
Publication of US20080306118A1 publication Critical patent/US20080306118A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Definitions

  • the present invention relates to production methods of an optically active sulfoxide compound having an antiulcer activity, a crystal of an optically active sulfoxide compound having remarkably improved stability, and the like.
  • JP-A-10-504290 (WO 96/02535) describes a production method of an optically active sulfoxide compound, which comprises subjecting a thio compound to an oxidation reaction, and crystallization (Example 11) of omeprazole, which comprises concentrating an acetonitrile solution and the like.
  • Lansoprazole is now on the market worldwide as a pharmaceutical product having a superior antiulcer activity.
  • the crystal of lansoprazole is a racemate and is superior in preservation stability.
  • a crystal of optically active (R)-lansoprazole and (S)-lansoprazole obtained according to the above-mentioned conventional method does not necessarily satisfy the preservation stability, with the undeniable possibility of decreased purity, increased amounts of analogous materials, coloring and the like during preservation.
  • the present invention provides the following:
  • [1] a method for producing a crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole or (S)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole, which comprises crystallizing at a temperature of about 0° C. to about 35° C.
  • FIG. 1 shows the appearance of a crystal (Example 1) having a melting start temperature of about 134° C. and a crystal (Reference Example 6) having a melting start temperature of about 130° C., before stability test (initial) and after stability test at 40° C. for 2 weeks, 50° C. for 2 weeks and 60° C. for 2 weeks.
  • the “(R)-lansoprazole” or “(S)-lansoprazole” used as a starting material in the crystal production method of the present invention can be produced according to a method known per se, such as the method described in JP-A-10-504290 (WO 96/02535) or a method analogous thereto, or the method described in the following production method 1 or 2.
  • the obtained compound can be isolated by a separation and purification method known per se, such as concentration, solvent extraction, crystallization, redissolution, chromatography or a combination thereof.
  • the method of optical resolution includes a method known per se, for example, a fractional recrystallization method, a chiral column method, a diastereomer method, and so forth.
  • the “fractional recrystallization method” includes a method in which a salt is formed between a racemate and an optically active compound [e.g., (+)-mandelic acid, ( ⁇ )-mandelic acid, (+)-tartaric acid, ( ⁇ )-tartaric acid, (+)-1-phenethylamine, ( ⁇ )-1-phenethylamine, cinchonine, ( ⁇ )-cinchonidine, brucine, etc.], which salt is separated by fractional recrystallization etc., and, if desired, subjected to a neutralization process, to give a free optical isomer.
  • an optically active compound e.g., (+)-mandelic acid, ( ⁇ )-mandelic acid, (+)-tartaric acid, ( ⁇ )-tartaric acid, (+)-1-phenethylamine, ( ⁇ )-1-phenethylamine, cinchonine, ( ⁇ )-cinchonidine, brucine, etc.
  • the “chiral column method” includes a method in which a racemate or a salt thereof is applied to a column for separation of optical isomer (chiral column).
  • a racemate for example, optical isomers are separated by adding a racemate to a chiral column such as ENANTIO-OVM (produced by Tosoh Corporation) or the DAICEL CHIRAL series (produced by Daicel Corporation), and developing the racemate in water, a buffer (e.g., phosphate buffer), an organic solvent (e.g., hexane, ethanol, methanol, isopropanol, acetonitrile, trifluoroacetic acid, diethylamine, triethylamine, etc.), or a solvent mixture thereof.
  • a chiral column such as CP-Chirasil-DeX CB (produced by GL Science), is used to separate optical isomers.
  • the “diastereomer method” includes a method in which a racemate and an optically active reagent are reacted (preferably, an optically active reagent is reacted with the 1-position of the benzimidazole group) to give a diastereomer mixture, which is then subjected to ordinary separation methods (e.g., fractional recrystallization, chromatography, etc.) to obtain either diastereomer, which is subjected to a chemical reaction (e.g., acid hydrolysis, base hydrolysis, hydrogenolysis, etc.) to cut off the optically active reagent moiety, whereby the desired optical isomer is obtained.
  • a chemical reaction e.g., acid hydrolysis, base hydrolysis, hydrogenolysis, etc.
  • Said “optically active reagent” includes, for example, optically active organic acids such as MTPA [ ⁇ -methoxy- ⁇ -(trifluoromethyl)phenylacetic acid] and ( ⁇ )-menthoxyacetic acid; and optically active alkoxymethyl halides such as (1R-endo)-2-(chloromethoxy)-1,3,3-trimethylbicyclo[2.2.1]heptane and the like.
  • optically active organic acids such as MTPA [ ⁇ -methoxy- ⁇ -(trifluoromethyl)phenylacetic acid] and ( ⁇ )-menthoxyacetic acid
  • optically active alkoxymethyl halides such as (1R-endo)-2-(chloromethoxy)-1,3,3-trimethylbicyclo[2.2.1]heptane and the like.
  • the (R)-lansoprazole or (S)-lansoprazole produced by the above-mentioned method may be a solid (crystal, amorphous) or an oily substance and may not be isolated or purified.
  • the crystal of (R)-lansoprazole or (S)-lansoprazole may or may not be a hydrate.
  • the “hydrate” includes 0.5 hydrate to 5.0 hydrate. Among others, 0.5 hydrate, 1.0 hydrate, 1.5 hydrate, 2.0 hydrate and 2.5 hydrate are preferred. More preferred is 0.5 hydrate, 1.0 hydrate and 1.5 hydrate.
  • the method of crystallization of crystal (I) includes methods known per se, for example, crystallization from a solution, crystallization from vapor, and crystallization from a molten form.
  • the method of the “crystallization from a solution” include, for example, a concentration method, a slow cooling method, a reaction method (diffusion method, electrolysis method), a hydrothermal growth method, a fusing agent method, and so forth.
  • the solvents to be used include, for example, aromatic hydrocarbons (e.g., benzene, toluene, xylene, etc.), halogenated hydrocarbons (e.g., dichloromethane, chloroform, etc.), saturated hydrocarbons (e.g., hexane, heptane, cyclohexane, etc.), ethers (e.g., diethyl ether, diisopropyl ether, tetrahydrofuran, dioxane, etc.), nitrites (e.g., acetonitrile, etc.), ketones (e.g., acetone, etc.), sulfoxides (e.g., dimethylsulfoxide, etc.), acid amides (e.g., N,N-dimethylformamide, etc.), esters (e.g., ethyl acetate, etc.), alcohols (e.g., methanol,
  • the method of the “crystallization from vapor” includes, for example, a gasification method (sealed tube method, gas stream method), a gas phase reaction method, a chemical transportation method, and so forth.
  • the method of the “crystallization from a molten form” includes, for example, a normal freezing method (pulling-up method, temperature gradient method, Bridgman method), a zone melting method (zone leveling method, float zone method), a special growth method (VLS method, liquid phase epitaxis method), and so forth.
  • Examples of the crystal of (R)-lansoprazole or (S)-lansoprazole to be used as a starting material in the crystal production method of the present invention include the following:
  • the enantiomeric excess of (R)-lansoprazole or (S)-lansoprazole to be applied to the crystal production method of the present invention is, for example, not less than about 80% ee, preferably not less than about 90% ee.
  • (R)-lansoprazole does not contain (S)-lansoprazole substantially.
  • does not contain substantially here is meant (S)-lansoprazole containing (R)-lansoprazole in 0-3%, preferably 0-1%.
  • a crystal of (R)-lansoprazole is selectively crystallized from a solution containing (R)-lansoprazole in a greater amount than (S)-lansoprazole and the precipitated crystal is separated to give a crystal of (R)-lansoprazole substantially free of (S)-lansoprazole.
  • a crystal of (S)-lansoprazole is selectively crystallized from a solution containing (S)-lansoprazole in a greater amount than (R)-lansoprazole and the precipitated crystal is separated to give a crystal of (S)-lansoprazole substantially free of (R)-lansoprazole.
  • the methods for “selective crystallization” include, for example, a method of stirring a solution, a method of adding a seed crystal to a solution, a method of changing the temperature of a solution, a method of changing the solvent composition of a solution, a method of decreasing the liquid amount of a solution, or a method consisting of two or more of these methods in combination and the like.
  • the “method of stirring a solution” includes, for example, stirring a solution containing one of (R)-lansoprazole and (S)-lansoprazole in a greater amount than the other at about ⁇ 80° C. to 120° C., preferably at about ⁇ 20° C. to 60° C., for about 0.01 to 100 hours, preferably for about 0.1 to 10 hours.
  • the “method of adding a seed crystal to a solution” include, for example, adding (1) a crystal showing an X-ray powder diffraction analysis pattern having characteristic peaks at interplanar spacings (d) of 5.88, 4.70, 4.35, 3.66 and 3.48 Angstrom; (2) a crystal showing an X-ray powder diffraction analysis pattern having characteristic peaks at interplanar spacings (d) of 8.33, 6.63, 5.86 and 4.82 Angstrom; (3) a mixture of the crystals of the aforementioned (1) and (2) or (4) in a solution, a solid that transforms to the aforementioned (1)-(3) (e.g., a crystal showing an X-ray powder diffraction analysis pattern having characteristic peaks at interplanar spacings (d) of 11.68, 6.77, 5.84, 5.73, 4.43, 4.09, 3.94, 3.89, 3.69, 3.41 and 3.11 Angstrom; a crystal showing an X-ray powder diffraction analysis pattern having characteristic peaks at interplanar spacings (d) of 8.86
  • the “method of changing the temperature of a solution” includes, for example, changing the temperature of a solution containing one of (R)-lansoprazole and (S)-lansoprazole in a greater amount than the other, preferably by cooling (e.g., lower the liquid temperature by 5-100° C.).
  • the “method of changing the solvent composition of a solution” includes, for example, adding water, a low polar organic solvent (e.g., esters, ethers, aromatic hydrocarbons, hydrocarbons, halogenated hydrocarbons or a mixture of two or more of these etc.) or a mixture of two or more of these to a solution containing one of (R)-lansoprazole and (S)-lansoprazole in a greater amount than the other.
  • a low polar organic solvent e.g., esters, ethers, aromatic hydrocarbons, hydrocarbons, halogenated hydrocarbons or a mixture of two or more of these etc.
  • the “method of decreasing the liquid amount of a solution” includes, for example, distilling away or evaporating the solvent from a solution containing one of (R)-lansoprazole and (S)-lansoprazole in a greater amount than the other and, the like.
  • a method of stirring a solution (i) a method of stirring a solution, (ii) a method comprising a method of stirring a solution and a method of adding a seed crystal to a solution, (iii) a method comprising a method of stirring a solution and a method of changing the temperature of a solution, (iv) a method comprising a method of stirring a solution and a method of changing the solvent composition of a solution, (v) a method comprising a method of stirring a solution and a method of decreasing the liquid amount of a solution, (vi) a method comprising a method of stirring a solution, a method of changing the temperature of a solution and a method of adding a seed crystal to a solution, (vii) a method comprising a method of stirring a solution, a method of changing the solvent composition of a solution and a method of adding a seed crystal to a solution, (viii) a method comprising a method of stirring a solution, a method of decreasing
  • the precipitated crystal can be separated by, for example, filtration, centrifugation and the like.
  • the thus-obtained crystal may be used as it is, or dried, where necessary, or may be subjected to a recrystallization step, where necessary.
  • the “drying” includes, for example, vacuum drying, through-flow drying, drying by heating, air drying and the like.
  • the obtained crystal or a dry crystal thereof is dissolved in a solvent (e.g., water, esters, ketones, phenols, alcohols, ethers, aromatic hydrocarbons, amides, sulfoxides, hydrocarbons, nitrites, halogenated hydrocarbons, pyridines or a mixture of two or more of these), applied to a dehydration step where necessary, and crystallized.
  • a solvent e.g., water, esters, ketones, phenols, alcohols, ethers, aromatic hydrocarbons, amides, sulfoxides, hydrocarbons, nitrites, halogenated hydrocarbons, pyridines or a mixture of two or more of these
  • the “dehydrating” is performed by a conventional dehydration method, such as a concentration method, a method using a dehydrating agent [e.g., anhydrous magnesium sulfate, anhydrous sodium sulfate, molecular sieve (trade name)] and the like.
  • a dehydrating agent e.g., anhydrous magnesium sulfate, anhydrous sodium sulfate, molecular sieve (trade name)] and the like.
  • crystallization method examples include the aforementioned crystallization method.
  • the amount of the analogous materials in the crystal is less than 1 wt %, preferably less than 0.4 wt %.
  • the crystal precipitated in the recrystallization step can be separated by, for example, filtration, centrifugation and the like.
  • the thus-obtained crystal may be used as it is, or dried, where necessary, or may be subjected to a second recrystallization step, where necessary.
  • drying is done by a method similar to the above-mentioned “drying”.
  • the obtained crystal is dissolved in a solvent (e.g., water, esters, ketones, phenols, alcohols, ethers, aromatic hydrocarbons, amides, sulfoxides, hydrocarbons, nitrites, halogenated hydrocarbons, pyridines or a mixture of two or more of these etc.), applied to a dehydration step where necessary, crystallized, separated and dried.
  • a solvent e.g., water, esters, ketones, phenols, alcohols, ethers, aromatic hydrocarbons, amides, sulfoxides, hydrocarbons, nitrites, halogenated hydrocarbons, pyridines or a mixture of two or more of these etc.
  • the “dehydrating” is performed by a method such as the above-mentioned “dehydration method”.
  • crystallization method examples include the aforementioned crystallization method.
  • the crystal obtained in the above-mentioned second recrystallization step is exemplified by a crystal of (R)- or (S)-lansoprazole, which shows an X-ray powder diffraction analysis pattern having characteristic peaks at interplanar spacings (d) of 11.68, 6.77, 5.84, 5.73, 4.43, 4.09, 3.94, 3.89, 3.69, 3.41 and 3.11 Angstrom.
  • the crystal obtained in the second recrystallization step may be separated by, for example, filtration, centrifugation and the like.
  • the separated crystal can be dried by, for example, vacuum drying, through-flow drying, drying by heating, air drying and the like.
  • esters include, for example, methyl acetate, ethyl acetate, propyl acetate, isopropyl acetate, butyl acetate, isobutyl acetate, ethyl formate and the like.
  • ketones include, for example, acetone, methyl ethyl ketone, methyl isopropyl ketone, methyl butyl ketone, methyl isobutyl ketone and the like.
  • the “phenols” include, for example, anisole and the like.
  • the “alcohols” include, for example, methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, 2-methyl-1-propanol, pentanol, 3-methyl-1-butanol, 2-methoxyethanol, 2-ethoxyethanol, ethylene glycol and the like.
  • ethers include, for example, t-butyl methyl ether, diethyl ether, 1,1-diethoxypropane, 1,1-dimethoxypropane, 2,2-dimethoxypropane, isopropyl ether, tetrahydrofuran, methyltetrahydrofuran and the like.
  • aromatic hydrocarbons include, for example, chlorobenzene, toluene, xylene, cumene and the like.
  • amides include, for example, formamide, N,N-dimethylacetamide, N,N-dimethylformamide, N-methylpyrrolidone and the like.
  • the “sulfoxides” include, for example, dimethylsulfoxide and the like.
  • hydrocarbons include, for example, propane, hexane, pentane, octane, isooctane and the like.
  • nitriles include, for example, acetonitrile and the like.
  • halogenated hydrocarbons include, for example, chloroform, dichloromethane, dichloroethene, trichloroethene and the like.
  • pyridines include, for example, pyridine and the like.
  • the crystal obtained by crystallization by the above-mentioned method and dry crystal thereof do not substantially contain the other enantiomer.
  • (R)-lansoprazole or (S)-lansoprazole is made to be present in C 1-4 alkyl acetate at a concentration of about 0.1 g/mL to about 0.5 g/mL (preferably about 0.1 g/mL to about 0.35 g/mL, more preferably about 0.2 g/mL to about 0.3 g/mL, particularly preferably about 0.25 g/mL to about 0.28 g/mL).
  • an excess C 1-4 alkyl acetate is added to (R)-lansoprazole or (S)-lansoprazole, and the mixture is heated where necessary at about 30° C. to 60° C. to dissolve same and concentrated under reduced pressure to achieve a given concentration (about 0.1 g/mL to about 0.5 g/mL).
  • the concentration is measured according to an area comparison method with a standard product solution using high performance liquid chromatography.
  • the measurement method is explained in detail in the following.
  • Standard solution standard product (about 75 mg) is precisely weighed and mobile phase is added to make the amount 100 mL.
  • Sample solution mobile phase is added to ethyl acetate solution (1 mL) to make the amount 100 mL.
  • Standard solution (10 ⁇ l) and sample solution (10 ⁇ l) are tested by liquid chromatography under the aforementioned HPLC conditions and peak area A S of (R)-lansoprazole or (S)-lansoprazole in the Standard solution, and the peak area A T Of (R)-lansoprazole or (S)-lansoprazole in the sample solution are measured by automatic integration, based on which the concentration of (R)-lansoprazole or (S)-lansoprazole is calculated from the following formula:
  • the concentration can be made to fall within the optimal range for the selected solvent, wherein the state of saturation or per-saturation (R)-lansoprazole or (S)-lansoprazole is preferable for crystallization.
  • the C 1-4 alkyl acetate includes methyl acetate, ethyl acetate, propyl acetate, butyl acetate and the like, of which preferably used are ethyl acetate and propyl acetate.
  • the crystallization is performed by standing or stirring a C 1-4 alkyl acetate solution containing the above-mentioned (R)-lansoprazole or (S)-lansoprazole according to a method known per se at a crystallization temperature of about 0° C. to about 35° C.
  • the lower limit of crystallization temperature is preferably about 10° C., more preferably about 15° C., most preferably about 20° C.
  • the upper limit of crystallization temperature is preferably about 30° C. Particularly, crystallization temperature is preferably about 20° C. to about 30° C.
  • the crystallization time is about 30 minutes to about 10 hours, preferably about 30 minutes to about 4 hours, particularly preferably about 1 hour to about 2 hours.
  • a seed crystal may be added to the solution.
  • the seed crystal include one that may be added to the solution before or during dropwise addition of C 5-8 hydrocarbon to be mentioned below.
  • This step is carried out in an atmosphere or under an inert gas atmosphere, or in an inert gas stream.
  • inert gas one usable for dropwise addition of C 5-8 hydrocarbon to be mentioned below is employed.
  • the crystal obtained by this step can be separated by a method such as filtration, centrifugation and the like.
  • the separated crystal may be washed, where necessary, with a (1:0-1:10) mixture of C 1-4 alkyl acetate-C 5-8 hydrocarbon, and the like.
  • the C 1-4 alkyl acetate here is exemplified by those mentioned above, and the C 5-8 hydrocarbon is exemplified by those mentioned below.
  • the separated crystal can be dried by, for example, vacuum drying, through-flow drying, drying by heating, air drying and the like.
  • the crystal obtained by this step is superior in preservation stability and can be used as the pharmaceutical product to be mentioned below.
  • step (2) the objective crystal superior in preservation stability can be obtained in a high yield.
  • the crystal By applying this step to the crystal obtained by the above-mentioned step (1) after separation or without separation, the crystal can be obtained in greater amounts.
  • This step is preferably applied after precipitation of the crystal in the above-mentioned step (1). It is preferably applied after precipitation of a crystal in at least about 20 wt %, more preferably about 30 wt % to about 90 wt %, particularly preferably about 50 wt % to about 90 wt %, of (R)-lansoprazole or (S)-lansoprazole added as a starting material.
  • the crystallization temperature in this step is the same as in step (1).
  • C 5-8 hydrocarbon examples include straight chain or branched C 5-8 aliphatic hydrocarbon, such as pentane, isopentane, neopentane, hexane, isohexane, 3-methylpentane, neohexane, 2,3-dimethylbutane, heptane, 2-methylhexane, 3-methylhexane, 3-ethylpentane, 2,2-dimethylpentane, 2,3-dimethylpentane, 2,4-dimethylpentane, 3,3-dimethylpentane, 2,2,3-trimethylbutane, octane, isooctane and the like, and C 7-8 aromatic hydrocarbon, such as toluene, xylene and the like.
  • heptane and straight chain C 5-8 aliphatic hydrocarbon such as hexane and the like, are used.
  • the amount of dropwise addition of C 5-8 hydrocarbon is not more than 7 times, preferably not more than 5 times, more preferably 1 to 3 times, the amount of the C 1-4 alkyl acetate solution containing (R)-lansoprazole or (S)-lansoprazole in step (1).
  • the dropwise addition includes sequential dropwise addition of almost the same amount over, for example, about 15 minutes to about 4 hours (preferably about 1 hour to about 2 hours) while standing or stirring the solution.
  • the temperature during dropwise addition is preferably adjusted to the above-mentioned crystallization temperature.
  • a seed crystal may be added to the solution before or during the dropwise addition of C 5-8 hydrocarbon.
  • the seed crystal includes, for example,
  • the mixture may be stood or stirred on demand for about 1 hour to about 3 hours.
  • This step is applied in an atmosphere or under an inert gas atmosphere, or in an inert gas stream.
  • the “inert gas” includes, for example, nitrogen, helium, neon, argon and the like.
  • the crystal obtained by this step can be separated by filtration, centrifugation and the like.
  • the separated crystal may be washed, where necessary, with a C 1-4 alkyl acetate-C 5-8 hydrocarbon (1:0-1:10) mixture and the like.
  • a C 1-4 alkyl acetate-C 5-8 hydrocarbon 1:0-1:10) mixture and the like.
  • the C 1-4 alkyl acetate and C 5-8 hydrocarbon are exemplified by those mentioned above.
  • the separated crystal can be dried by, for example, vacuum drying, through-flow drying, drying by heating, air drying and the like.
  • the obtained crystal can be analyzed generally by crystal analysis by X-ray diffraction.
  • the orientation of the crystal can be determined by a mechanical method, optical method and the like.
  • the crystal obtained by the above-mentioned production method has the following melting start temperature by DSC measurement (temperature rise rate 0.5° C./min).
  • the “melting start temperature” refers to the temperature at which crystals start to melt when heated under, for example, the DSC measurement conditions to be mentioned below.
  • the crystal has the melting start temperature of not less than about 131° C., preferably about 131° C. to about 137° C., more preferably about 132° C. to about 135° C., most preferably about 133° C. to about 135° C., particularly preferably about 135° C.
  • the melting start temperature of the crystal obtained in the above-mentioned step (1) can be about 135° C.
  • the melting start temperature of the crystal obtained by step (2) after applying the above-mentioned step (1) can be about 132° C. to about 135° C.
  • the melting start temperature of the crystal obtained by a conventional method is less than about 131° C.
  • the melting start temperature of the crystal obtained by the method of Reference Example 3 mentioned below was about 125° C. to about 130° C.
  • the crystal having a melting start temperature of not less than about 131° C. which is obtained by the production method of the present invention, has extremely superior preservation stability as compared to the crystal having a melting start temperature of less than about 131° C., which is obtained by a prior art method.
  • the crystal obtained by the production method of the present invention showed a residual ratio of not less than 99%, but the ratio of the crystal obtained by a conventional method was less than 94%.
  • the crystal obtained by a conventional method showed noticeable coloring during preservation.
  • the crystal having a melting start temperature of not less than about 131° C., which is obtained by the production method of the present invention, has such superior preservation stability and can be used advantageously as a pharmaceutical product, as compared to the crystal having a melting start temperature of less than about 131° C., which is obtained by a prior art method.
  • the crystal of (R)-lansoprazole or (S)-lansoprazole obtained by the crystal production method of the present invention is useful as a pharmaceutical product because it shows excellent antiulcer activity, gastric acid secretion-inhibiting action, mucosa-protecting action, anti- Helicobacter pylori action, etc., and because it is of low toxicity.
  • the dry crystal of (R)-lansoprazole or (S)-lansoprazole is stabler than a precipitated crystal (wet crystal) of (R)-lansoprazole or (S)-lansoprazole, and when it is used as a pharmaceutical product, a dry crystal of (R)-lansoprazole or (S)-lansoprazole is preferably used.
  • the crystal or dry crystal obtained by the method of the present invention is useful for mammals (e.g., humans, monkeys, sheep, bovines, horses, dogs, cats, rabbits, rats, mice, etc.) in the treatment and prevention of digestive ulcer (e.g., gastric ulcer, duodenal ulcer, stomach ulcer, Zollinger-Ellison syndrome, etc.), gastritis, reflux esophagitis, NUD (non-ulcer dyspepsia), gastric cancer (inclusive of gastric cancer caused by promotion of interleukin-1 ⁇ production due to genetic polymorphism of interleukin-1) and gastric MALT lymphoma; Helicobacter pylori eradication; suppression of upper gastrointestinal hemorrhage due to digestive ulcer, acute stress ulcer and hemorrhagic gastritis; suppression of upper gastrointestinal hemorrhage due to invasive stress (stress from major surgery necessitating intensive management after surgery, and from cerebral vascular disorder, head trauma, multiple organ failure and extensive burn nec
  • the crystal or dry crystal obtained by the method of the present invention and antibiotic penicillins (e.g., amoxicillin etc.) and antibiotic erythromycins (e.g., clarithromycin, etc.) are preferably used.
  • antibiotic penicillins e.g., amoxicillin etc.
  • antibiotic erythromycins e.g., clarithromycin, etc.
  • the crystal of (R)-lansoprazole is preferably used.
  • the crystal of the present invention can be safely administered orally or non-orally (e.g., topical, rectal and intravenous administration, etc.), as such or in the form of pharmaceutical compositions formulated with a pharmacologically acceptable carrier, e.g., tablets (including sugar-coated tablets and film-coated tablets), powders, granules, capsules (including soft capsules), orally disintegrating tablets, liquids, injectable preparations, suppositories, sustained-release preparations and patches, in accordance with a commonly known method.
  • a pharmacologically acceptable carrier e.g., tablets (including sugar-coated tablets and film-coated tablets), powders, granules, capsules (including soft capsules), orally disintegrating tablets, liquids, injectable preparations, suppositories, sustained-release preparations and patches, in accordance with a commonly known method.
  • the content of the crystal of the present invention in the pharmaceutical composition of the present invention is about 0.01 to 100 wt % relative to the entire composition. Varying depending on subject of administration, route of administration, target disease etc., its dose is normally about 0.5 to 1,500 mg/day, preferably about 5 to 150 mg/day, based on the active ingredient, when, for example, it is orally administered as an antiulcer agent to an adult human (60 kg).
  • the crystal of the present invention may be administered once daily or in 2 to 3 divided portions per day.
  • Pharmacologically acceptable carriers that may be used to produce the pharmaceutical composition of the present invention include various organic or inorganic carrier substances in common use as pharmaceutical materials, including excipients, lubricants, binders, disintegrants, water-soluble polymers and basic inorganic salts for solid preparations; and solvents, dissolution aids, suspending agents, isotonicity agents, buffers and soothing agents for liquid preparations.
  • Other ordinary pharmaceutical additives such as preservatives, antioxidants, coloring agents, sweetening agents, souring agents, bubbling agents and flavorings may also be used as necessary.
  • excipients include, for example, lactose, sucrose, D-mannitol, starch, cornstarch, crystalline cellulose, light silicic anhydride, titanium oxide and the like.
  • Such “lubricants” include, for example, magnesium stearate, sucrose fatty acid esters, polyethylene glycol, talc, stearic acid and the like.
  • binder include, for example, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, crystalline cellulose, ⁇ -starch, polyvinylpyrrolidone, gum arabic powder, gelatin, pullulan, low-substituted hydroxypropyl cellulose and the like.
  • Such “disintegrants” include (1) crosslinked povidone, (2) what is called super-disintegrants such as crosslinked carmellose sodium (FMC-Asahi Chemical) and carmellose calcium (Gotoku Yakuhin), (3) carboxymethyl starch sodium (e.g., product of Matsutani Chemical), (4) low-substituted hydroxypropyl cellulose (e.g., product of Shin-Etsu Chemical), (5) cornstarch, and so forth.
  • super-disintegrants such as crosslinked carmellose sodium (FMC-Asahi Chemical) and carmellose calcium (Gotoku Yakuhin)
  • carboxymethyl starch sodium e.g., product of Matsutani Chemical
  • low-substituted hydroxypropyl cellulose e.g., product of Shin-Etsu Chemical
  • Said “crosslinked povidone” may be any crosslinked polymer having the chemical name 1-ethenyl-2-pyrrolidinone homopolymer, including, what is called, polyvinylpyrrolidone (PVPP) and 1-vinyl-2-pyrrolidinone homopolymer, and is exemplified by Colidon CL (produced by BASF), Polyplasdon XL (produced by ISP), Polyplasdon XL-10 (produced by ISP), Polyplasdon INF-10 (produced by ISP) and the like.
  • PVPP polyvinylpyrrolidone
  • Colidon CL produced by BASF
  • Polyplasdon XL produced by ISP
  • Polyplasdon XL-10 produced by ISP
  • Polyplasdon INF-10 produced by ISP
  • water-soluble polymers include, for example, ethanol-soluble water-soluble polymers [e.g., cellulose derivatives such as hydroxypropyl cellulose (hereinafter also referred to as HPC), polyvinylpyrrolidone etc.], ethanol-insoluble water-soluble polymers [e.g., cellulose derivatives such as hydroxypropylmethyl cellulose (hereinafter also referred to as HPMC), methyl cellulose and carboxymethyl cellulose sodium, sodium polyacrylate, polyvinyl alcohol, sodium alginate, guar gum etc.] and the like.
  • HPC hydroxypropyl cellulose
  • HPMC hydroxypropylmethyl cellulose
  • HPMC hydroxypropylmethyl cellulose
  • Such “basic inorganic salts” include, for example, basic inorganic salts of sodium, potassium, magnesium and/or calcium. Preferred are basic inorganic salts of magnesium and/or calcium. More preferred are basic inorganic salts of magnesium. Such basic inorganic salts of sodium include, for example, sodium carbonate, sodium hydrogen carbonate, disodium hydrogenphosphate, etc. Such basic inorganic salts of potassium include, for example, potassium carbonate, potassium hydrogen carbonate, etc.
  • Such basic inorganic salts of magnesium include, for example, heavy magnesium carbonate, magnesium carbonate, magnesium oxide, magnesium hydroxide, magnesium metasilicate aluminate, magnesium silicate, magnesium aluminate, synthetic hydrotalcite [Mg 6 Al 2 (OH) 16 .CO 3 .4H 2 O], alumina hydroxide magnesium, and so forth.
  • preferred is heavy magnesium carbonate, magnesium carbonate, magnesium oxide, magnesium hydroxide, etc.
  • Such basic inorganic salts of calcium include, for example, precipitated calcium carbonate, calcium hydroxide and the like.
  • solvents include, for example, water for injection, alcohol, propylene glycol, macrogol, sesame oil, corn oil, olive oil and the like.
  • dissolution aids include, for example, polyethylene glycol, propylene glycol, D-mannitol, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, sodium citrate and the like.
  • Such “suspending agents” include, for example, surfactants such as stearyltriethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride and monostearic glycerol; and hydrophilic polymers such as polyvinyl alcohol, polyvinylpyrrolidone, carboxymethyl cellulose sodium, methyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose and hydroxypropyl cellulose.
  • Such “isotonicity agents” include, for example, glucose, D-sorbitol, sodium chloride, glycerol, D-mannitol and the like.
  • buffers include, for example, buffer solutions of phosphates, acetates, carbonates, citrates and the like.
  • Such “soothing agents” include, for example, benzyl alcohol and the like.
  • Such “preservatives” include, for example, p-oxybenzoic acid esters, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid and the like.
  • antioxidants include, for example, sulfites, ascorbic acid, ⁇ -tocopherol and the like.
  • Such “coloring agents” include, for example, foodcolors such as Food Color Yellow No. 5, Food Color Red No. 2 and Food Color Blue No. 2; and food lake colors, Bengal and the like.
  • sweetening agents include, for example, saccharin sodium, dipotassium glycyrrhetinate, aspartame, stevia, thaumatin and the like.
  • Such “souring agents” include, for example, citric acid (citric anhydride), tartaric acid, malic acid and the like.
  • Such “bubbling agents” include, for example, sodium bicarbonate and the like.
  • Such “flavorings” may be synthetic substances or naturally occurring substances, and include, for example, lemon, lime, orange, menthol, strawberry and the like.
  • the crystal of the present invention may be prepared as a preparation for oral administration in accordance with a commonly known method, by, for example, compression-shaping it in the presence of an excipient, a disintegrant, a binder, a lubricant or the like, and subsequently coating it as necessary by a commonly known method for the purpose of taste masking, enteric dissolution or sustained release.
  • a commonly known method for an enteric preparation, an intermediate layer may be provided by a commonly known method between the enteric layer and the drug-containing layer for the purpose of separation of the two layers.
  • available method include, for example, a method in which a core containing crystalline cellulose and lactose is coated with the crystal of the present invention and a basic inorganic salt, and is further coated with a coating layer containing a water-soluble polymer, to give a composition, which is coated with an enteric coating layer containing polyethylene glycol, further coated with an enteric coating layer containing triethyl citrate, still further coated with an enteric coating layer containing polyethylene glycol, and still yet further coated with mannitol, to give fine granules, which are mixed with additives and shaped.
  • enteric coating layer includes, for example, aqueous enteric polymer substrates such as cellulose acetate phthalate (CAP), hydroxypropylmethyl cellulose phthalate, hydroxymethyl cellulose acetate succinate, methacrylic acid copolymers [e.g., Eudragit L30D-55 (trade name; produced by Rohm), Colicoat MAE30DP (trade name; produced by BASF), Polykid PA30 (trade name; produced by San-yo Chemical) etc.], carboxymethylethyl cellulose and shellac; sustained-release substrates such as methacrylic acid polymers [e.g., Eudragit NE30D (trade name), Eudragit RL30D (trade name), Eudragit RS30D (trade name), etc.]; water-soluble polymers; plasticizers such as triethyl citrate, polyethylene glycol, acetylated monoglycerides, triacetine and castor oil; and mixtures of one or more thereof
  • additive includes, for example, water-soluble sugar alcohols (e.g., sorbitol, mannitol, multitol, reduced starch saccharides, xylitol, reduced paratinose, erythritol. etc.), crystalline cellulose [e.g., sorbitol, mannitol, multitol, reduced starch saccharides, xylitol, reduced paratinose, erythritol. etc.), crystalline cellulose [e.g.
  • the crystal of the present invention may be used in combination with 1 to 3 other active ingredients.
  • Such “other active ingredients” include, for example, anti- Helicobacter pylori activity substances, imidazole compounds, bismuth salts, quinolone compounds, and so forth. Of these substances, preferred are anti- Helicobacter pylori action substances, imidazole compounds etc.
  • anti- Helicobacter pylori action substances include, for example, antibiotic penicillins (e.g., amoxicillin, benzylpenicillin, piperacillin, mecillinam, etc.), antibiotic cefems (e.g., cefixime, cefaclor, etc.), antibiotic macrolides (e.g., erythromycin.
  • antibiotic tetracyclines e.g., tetracycline, minocycline, streptomycin. etc.
  • antibiotic aminoglycosides e.g., gentamicin, amikacin, etc.
  • imipenem e.g., imipenem, and so forth.
  • antibiotic penicillins antibiotic macrolides etc.
  • a triple therapy of an antibiotic penicillins, an antibiotic macrolide and the crystal of (R)-lansoprazole or (S)-lansoprazole Especially preferred is a triple therapy of an antibiotic penicillins, an antibiotic macrolide and the crystal of (R)-lansoprazole or (S)-lansoprazole.
  • imidazole compounds include, for example, metronidazole, miconazole, etc.
  • bismuth salts include, for example, bismuth acetate, bismuth citrate, etc.
  • quinolone compounds include, for example, ofloxacin, ciploxacin,
  • Such “other active ingredients” and the crystal of the present invention may also be used in combination as a mixture prepared as a single pharmaceutical composition [e.g., tablets. powders, granules, capsules (including soft capsules), liquids, injectable preparations, suppositories, sustained-release preparations, etc.], in accordance with a commonly known method. and may also be prepared as separate preparations and administered to the same subject simultaneously or at a time interval.
  • a pharmaceutical composition e.g., tablets. powders, granules, capsules (including soft capsules), liquids, injectable preparations, suppositories, sustained-release preparations, etc.
  • the X-ray powder diffraction was measured using X-ray Diffractometer RINT Ultima+ (Rigaku).
  • the melting start temperature was measured using DSC (differential scanning calorimeter SEIKO DSC220C) under the following measurement conditions.
  • sample container aluminum pan (without cover)
  • Enantiomeric excess (% ee) was measured by high performance liquid chromatography using an optically active column for the following conditions (A).
  • the amounts of sulfide and sulfone present were measured by high performance liquid chromatography using an optically active column for the following conditions (A) or high performance liquid chromatography under the conditions (B).
  • Diisopropylethylamine (815 mL, 4.68 mol) was added under a nitrogen gas stream at 15-25° C., and cumene hydroperoxide (7.65 L, content 82%, 42.7 mol) was added at ⁇ 10° C. to 5° C. and the mixture was stirred at ⁇ 8° C. to 2° C. for 3 hours to allow reaction.
  • condition (A) The analysis results of the reaction mixture by high performance liquid chromatography (conditions (A)) are as follows.
  • aqueous ammonia (12 L, about 50° C.) was added to the organic layer and the mixture was partitioned (this step was repeated once).
  • the aqueous layers were combined, ethyl acetate (24.5 L) was added, and acetic acid was added dropwise at not more than 20° C. to adjust the pH to about 8.
  • the aqueous layer was extracted with ethyl acetate (24.5 L).
  • the organic layers were combined and washed with about 20% brine (24.5 L).
  • triethylamine 250 mL
  • Acetone (5.55 L) was added to the concentrate and the mixture was concentrated under reduced pressure.
  • the concentrate was dissolved in acetone (10 L) and the solution was added dropwise to a mixture of acetone (5 L) and water (25 L). Water (20 L) was added dropwise to the obtained mixture. The precipitated crystal was separated and successively washed with cooled acetone-water (1:3, 4 L) and water (13 L).
  • the wet crystal obtained by the method of the above-mentioned Reference Example 2 was dissolved in ethyl acetate (43 L). The separated aqueous layer was partitioned and the obtained organic layer was concentrated under reduced pressure until the liquid amount became about 19 L. Ethyl acetate (48 L) was added to the concentrate, and the mixture was concentrated under reduced pressure until the liquid amount became about 19 L. Ethyl acetate (48 L) and activated carbon (360 g) were added to the concentrate and the mixture was stirred and the activated carbon was filtered off. The filtrate was concentrated under reduced pressure until the liquid amount became about 19 L. Heptane (150 L) was added dropwise to the concentrate at about 40° C. The mixture was stirred at the same temperature for about 30 minutes and the crystal was separated and washed with ethyl acetate-heptane (1:8, 8 L, about 40° C.) and dried to give the title compound (4.5 kg).
  • the crystal showed an X-ray powder diffraction analysis pattern having characteristic peaks at interplanar spacings (d) of 11.68, 6.77, 5.84, 5.73, 4.43, 4.09, 3.94, 3.89, 3.69, 3.41 and 3.11 Angstrom.
  • the melting start temperature of the crystal was 127.5° C.
  • the wet crystal showed an X-ray powder diffraction analysis pattern having characteristic peaks at interplanar spacings (d) of 5.88, 4.70, 4.35, 3.66 and 3.48 Angstrom.
  • the crystal showed an X-ray powder diffraction analysis pattern having characteristic peaks at interplanar spacings (d) of 8.33, 6.63, 5.86 and 4.82 Angstrom.
  • the wet crystal (containing the title compound 35.37 g, content of analogous materials: 0%, enantiomeric excess: 100% ee) obtained according to Reference Example 4 was dissolved in ethyl acetate (340 mL). The aqueous layer was separated by partitioning and the obtained organic layer was concentrated under reduced pressure until the liquid amount became about 100 mL. Ethyl acetate (400 mL) and activated carbon (3 g) were added to the concentrate and the mixture was stirred. The activated carbon was removed by filtration. The filtrate was concentrated under reduced pressure until the liquid amount became about 100 mL. Heptane (1000 mL) was added dropwise to the concentrate at about 40° C.
  • the crystal showed an X-ray powder diffraction analysis pattern having characteristic peaks at interplanar spacings (d) of 11.68, 6.77, 5.84, 5.73, 4.43, 4.09, 3.94, 3.89, 3.69, 3.41 and 3.11 Angstrom.
  • the melting start temperature of the crystal was 127.0° C.
  • the crystal showed an X-ray powder diffraction analysis pattern having characteristic peaks at interplanar spacings (d) of 11.68, 6.77, 5.84, 5.73, 4.43, 4.09, 3.94, 3.89, 3.69, 3.41 and 3.11 Angstrom.
  • the melting start temperature of the crystal was 130.0° C.
  • the crystal showed an X-ray powder diffraction analysis pattern having characteristic peaks at interplanar spacings (d) of 11.68, 6.77, 5.84, 5.73, 4.43, 4.09, 3.94, 3.89, 3.69, 3.41 and 3.11 Angstrom.
  • the melting start temperature of the crystal was 128.5° C.
  • the wet crystal obtained according to the method of the above-mentioned Reference Example 2 was dissolved in ethyl acetate (50 L). The mixture was partitioned and the organic layer was concentrated under reduced pressure until the liquid amount became about 25 L. Ethyl acetate (30 L) was added to the concentrate, and the mixture was concentrated under reduced pressure until the liquid amount became about 15 L. Ethyl acetate (30 L) and activated carbon (150 g) were added to the concentrate. The activated carbon was removed and the mixture was washed with ethyl acetate (1.5 L).
  • the crystal showed an X-ray powder diffraction analysis pattern having characteristic peaks at interplanar spacings (d) of 11.68, 6.77, 5.84, 5.73, 4.43, 4.09, 3.94, 3.89, 3.69, 3.41 and 3.11 Angstrom.
  • the crystal showed an X-ray powder diffraction analysis pattern having characteristic peaks at interplanar spacings (d) of 11.68, 6.77, 5.84, 5.73, 4.43, 4.09, 3.94, 3.89, 3.69, 3.41 and 3.11 Angstrom.
  • interplanar spacings (d) 11.68, 6.77, 5.84, 5.73, 4.43, 4.09, 3.94, 3.89, 3.69, 3.41 and 3.11 Angstrom.
  • analogous materials such as sulfone, sulfide and the like were not found.
  • the enantiomeric excess of (R)-lansoprazole in the crystal was 100% ee.
  • the melting start temperature of the crystal was 135.0° C.
  • the melting start temperature of the crystal was 134.5° C.
  • the melting start temperature of the crystal was 133.5° C.
  • the melting start temperature of the crystal was 133.5° C.
  • the melting start temperature of the crystal was 134.0° C.
  • the melting start temperature of the crystal was 133.0° C.
  • the melting start temperature of the crystal was 133.0° C.
  • the melting start temperature of the crystal was 134.0° C.
  • the wet crystal obtained according to the method of the above-mentioned Reference Example 4 was dissolved in ethyl acetate (50 L). The mixture was partitioned and the organic layer was concentrated under reduced pressure until the liquid amount became about 27 L. Ethyl acetate (30 L) was added to the concentrate, and the mixture was concentrated under reduced pressure until the liquid amount became about 16 L. Ethyl acetate (30 L) and activated carbon (150 g) were added to the concentrate. The activated carbon was removed and the mixture was washed with ethyl acetate (1.5 L).
  • the crystal showed an X-ray powder diffraction analysis pattern having characteristic peaks at interplanar spacings (d) of 11.68, 6.77, 5.84, 5.73, 4.43, 4.09, 3.94, 3.89, 3.69, 3.41 and 3.11 Angstrom.
  • the melting start temperature of the crystal was 133.5° C.
  • the melting start temperature of the crystal was 133.5° C.
  • the crystal obtained by the method of the present invention shows a residual ratio of not less than 99% in a 60° C. one month stability test.
  • the crystal obtained by a conventional method shows a residual ratio decreased to about 90-94%.
  • FIG. 1 the appearance of a crystal (Example 1) having a melting start temperature of about 134° C. and a crystal (Reference Example 6) having a melting start temperature of about 130° C. before stability test and after stability tests (40° C. 2 weeks, 50° C. 2 weeks and 60° C. 2 weeks) is shown.
  • the crystal having a melting start temperature of about 134° C. did not show changes in the appearance but the crystal having a melting start temperature of about 130° C. showed appreciably degraded appearance.
  • Capsules (15 mg) were obtained according to the charge amount-1 in the following Table 3 and the following method (in Table 4, amounts per capsule are shown).
  • a centrifugal fluidized coating granulator was charged (2) Nonpareil and the above-mentioned dusting powder was coated while spraying an aqueous solution of (7) hydroxypropyl cellulose in purified water.
  • the spherical granules were dried in vacuo at 40° C. for 16-20 hours and passed through a sieve (600 ⁇ m, 1180 ⁇ m) to give base granules.
  • the base granules were placed in a roll flow type coating machine and coated with a suspension of (8) methacrylic acid copolymer LD-(12) polysorbate 80 in purified water.
  • the coated granules were passed through a sieve (710 ⁇ m, 1400 ⁇ m) and dried in vacuo at 40° C. for 16-20 hours to give enteric coated granules.
  • Capsules (15 mg) were obtained according to the charge amount-2 in the following Table 5 and the following method (in Table 6, amounts per capsule are shown).
  • Compound A and the ingredients (3) to (6) were thoroughly mixed to give a main drug dusting powder.
  • the ingredients (7) to (9) were thoroughly mixed to give a cover coating agent.
  • In a centrifugal fluidized coating granulator was charged (2)
  • Nonpareil and the above-mentioned main drug dusting powder and the cover coating agent were successively coated while spraying an aqueous solution of (10) hydroxypropyl cellulose in purified water.
  • the spherical granules were dried in vacuo at 40° C.
  • the base granules were placed in a roll flow type coating machine and coated with a suspension of (11) methacrylic acid copolymer LD-(15) polysorbate 80 in purified water.
  • the coated granules were passed through a sieve (710 ⁇ m, 1400 ⁇ m) and dried in vacuo at 40° C. for 16-20 hours to give enteric-coated granules.
  • To the enteric coated granules were added (16) talc and (17) light silicic anhydride and mixed granules were produced in a tumbler mixer.
  • the mixed granules were filled in (18) HPMC Capsule No. 2 by a capsule filling machine to give 15 mg capsules.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
US11/899,918 2000-12-01 2007-09-07 Process for the crystallization of (R) - or (S) - Lansoprazole Abandoned US20080306118A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/899,918 US20080306118A1 (en) 2000-12-01 2007-09-07 Process for the crystallization of (R) - or (S) - Lansoprazole

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP367757/2000 2000-12-01
JP2000367757 2000-12-01
PCT/JP2001/010462 WO2002044167A1 (en) 2000-12-01 2001-11-30 Process for the crystallization of (r)- or (s)-lansoprazole
US10/432,798 US7285668B2 (en) 2000-12-01 2001-11-30 Process for the crystallization of (R)- or (S)-lansoprazole
US11/899,918 US20080306118A1 (en) 2000-12-01 2007-09-07 Process for the crystallization of (R) - or (S) - Lansoprazole

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US10/432,798 Division US7285668B2 (en) 2000-12-01 2001-11-30 Process for the crystallization of (R)- or (S)-lansoprazole
PCT/JP2001/010462 Division WO2002044167A1 (en) 2000-12-01 2001-11-30 Process for the crystallization of (r)- or (s)-lansoprazole

Publications (1)

Publication Number Publication Date
US20080306118A1 true US20080306118A1 (en) 2008-12-11

Family

ID=18838123

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/432,798 Expired - Lifetime US7285668B2 (en) 2000-12-01 2001-11-30 Process for the crystallization of (R)- or (S)-lansoprazole
US11/899,918 Abandoned US20080306118A1 (en) 2000-12-01 2007-09-07 Process for the crystallization of (R) - or (S) - Lansoprazole

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/432,798 Expired - Lifetime US7285668B2 (en) 2000-12-01 2001-11-30 Process for the crystallization of (R)- or (S)-lansoprazole

Country Status (17)

Country Link
US (2) US7285668B2 (tr)
EP (2) EP1337525B8 (tr)
KR (3) KR20100002278A (tr)
CN (1) CN1254473C (tr)
AT (1) ATE511508T1 (tr)
AU (1) AU2002218506A1 (tr)
CA (1) CA2436825C (tr)
CY (1) CY1112347T1 (tr)
DK (1) DK1337525T3 (tr)
ES (1) ES2367419T3 (tr)
HK (1) HK1054380B (tr)
HU (1) HU229356B1 (tr)
NO (1) NO326019B1 (tr)
PL (3) PL399787A1 (tr)
PT (1) PT1337525E (tr)
TW (1) TWI290922B (tr)
WO (1) WO2002044167A1 (tr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012001705A2 (en) 2010-06-29 2012-01-05 Cadila Healthcare Limited Pharmaceutical compositions of (r)-lansoprazole
CN104997739A (zh) * 2015-08-31 2015-10-28 青岛蓝盛洋医药生物科技有限责任公司 一种治疗消化系统疾病的药物兰索拉唑组合物冻干粉针剂
US9920196B2 (en) 2013-06-20 2018-03-20 Japan Polypropylene Corporation Propylene-based block copolymer

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020027315A1 (en) * 2000-03-10 2002-03-07 Parker Gerard E. Low-firing temperature method for producing Al2O3 bodies having enhanced chemical resistance
EP1293507B1 (en) 2000-05-15 2007-11-28 Takeda Pharmaceutical Company Limited Process for producing crystal
PL373539A1 (en) * 2002-03-27 2005-09-05 Teva Pharmaceutical Industries Ltd. Lansoprazole polymorphs and processes for preparation thereof
AU2003273000A1 (en) 2002-10-16 2004-05-04 Takeda Pharmaceutical Company Limited Stable solid preparations
AU2004207720A1 (en) * 2003-01-31 2004-08-12 Teijin Pharma Limited Crystal of (23S)-1alpha-hydroxy-27-nor-25-methylenevitamin D3-26,23-lactone and process for producing the same
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2531566C (en) * 2003-07-18 2013-05-07 Santarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
MXPA06000529A (es) * 2003-07-18 2006-08-11 Santarus Inc Formulaciones farmaceuticas utiles para inhibir la secrecion de acido y metodos para elaborarlas y utilizarlas.
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
EP1718303A4 (en) * 2004-02-10 2010-09-01 Santarus Inc COMBINATION OF INHIBITOR OF PROTON PUMP, BUFFER AND NON-STEROIDAL ANTI-INFLAMMATORY DRUG
MXPA06011820A (es) * 2004-04-16 2006-12-15 Santarus Inc Combinacion de inhibidor de bomba de proton, agente regulador del ph y agente procinetico.
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AU2005264864B2 (en) 2004-06-16 2011-08-11 Takeda Pharmaceutical Company Limited Multiple PPI dosage form
EP1681056A1 (en) * 2005-01-14 2006-07-19 Krka Tovarna Zdravil, D.D., Novo Mesto Process for preparing lansoprazole
JP2009511481A (ja) * 2005-10-06 2009-03-19 オースペックス・ファーマシューティカルズ・インコーポレイテッド 増強された治療特性を持つ、胃Ｈ＋，Ｋ＋−ＡＴＰａｓｅの重水素化阻害剤
US20090175959A1 (en) 2005-12-28 2009-07-09 Takeda Pharmaceutical Company Limited Controlled Release Solid Preparation
KR100758600B1 (ko) * 2006-01-05 2007-09-13 주식회사 대웅제약 란소프라졸 결정형 ａ의 제조방법
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
JP5366558B2 (ja) 2006-12-28 2013-12-11 武田薬品工業株式会社 口腔内崩壊性固形製剤
WO2008087665A2 (en) * 2007-01-18 2008-07-24 Matrix Laboratories Ltd Process for preparation of lansoprazole
KR101303813B1 (ko) 2007-04-16 2013-09-04 에스케이케미칼주식회사 라세믹 오메프라졸로부터 에스오메프라졸의 개선된제조방법
RU2013106514A (ru) * 2007-10-12 2015-03-10 Такеда Фармасьютикалз Норт Америка, Инк. Способы лечения нарушений желудочно-кишечного тракта независимо от потребления пищи
NZ593629A (en) * 2007-12-18 2012-11-30 Watson Pharma Private Ltd Stable amorphous R-lansoprazole prepared by optically resolving racemic lansoprazole
BRPI0909651A2 (pt) 2008-03-10 2015-09-22 Takeda Pharmaceutical cristal, agente farmacêutico, método para tratar ou evitar doença, uso do cristal, e, método para a produção de um cristal
AU2009336561A1 (en) 2008-05-14 2010-07-15 Watson Pharma Private Limited Stable R-(+)-lansoprazole amine salt and a process for preparing the same
US20100113527A1 (en) * 2008-09-30 2010-05-06 Teva Pharmaceutical Industries Ltd. Crystalline forms of dexlansoprazole
KR101321055B1 (ko) * 2008-11-14 2013-10-23 한미사이언스 주식회사 덱스란소프라졸의 신규 결정형 및 이를 포함하는 약학 조성물
IT1391776B1 (it) * 2008-11-18 2012-01-27 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo
WO2010095144A2 (en) * 2009-02-04 2010-08-26 Msn Laboratories Limited Process for the preparation of proton pump inhibitors
IT1392813B1 (it) * 2009-02-06 2012-03-23 Dipharma Francis Srl Forme cristalline di dexlansoprazolo
US20110009637A1 (en) * 2009-02-10 2011-01-13 Dario Braga Crystals of Dexlansoprazole
WO2011004387A2 (en) 2009-06-18 2011-01-13 Matrix Laboratories Ltd Process for the preparation of dexlansoprazole polymorphic forms
IT1395118B1 (it) * 2009-07-29 2012-09-05 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo cristallino
WO2011092665A1 (en) 2010-01-29 2011-08-04 Ranbaxy Laboratories Limited Process for the preparation of crystalline forms of dexlansoprazole
AU2011234003B2 (en) * 2010-03-31 2013-09-19 Sun Pharmaceutical Industries Limited Process for the preparation of dexlansoprazole
AU2011234001B2 (en) 2010-03-31 2014-08-28 Sun Pharmaceutical Industries Limited Salts of dexlansoprazole and their preparation
KR101908748B1 (ko) 2010-12-03 2018-10-16 다케다 야쿠힌 고교 가부시키가이샤 구강내 붕괴정
BR112013014875A2 (pt) 2010-12-27 2016-10-18 Takeda Pharmaceutical tablete oralmente desintegrável
WO2012104805A1 (en) 2011-02-01 2012-08-09 Ranbaxy Laboratories Limited Process for the preparation of dexlansoprazole
AU2012274967A1 (en) 2011-06-21 2014-01-23 Sun Pharmaceutical Industries Limited Process for the preparation of dexlansoprazole
CN102234265B (zh) * 2011-08-08 2013-11-20 天津市汉康医药生物技术有限公司 兰索拉唑化合物
JP5925318B2 (ja) 2011-11-30 2016-05-25 武田薬品工業株式会社 有核錠
CN104025155B (zh) 2011-12-29 2017-07-25 英特尔公司 可变深度压缩
WO2013140120A1 (en) 2012-03-22 2013-09-26 Cipla Limited Glycerol solvate forms of (r) - 2 - [ [ [3 -methyl -4 (2,2, 2 - trifluoroethoxy) pyridin- 2 - yl] methyl] sulphinyl] - 1h - ben zimidazole
WO2013179194A1 (en) 2012-05-31 2013-12-05 Ranbaxy Laboratories Limited Process for the preparation of crystalline dexlansoprazole
CN105392486A (zh) 2013-05-21 2016-03-09 武田药品工业株式会社 口腔崩解片
CN103254174B (zh) * 2013-06-05 2014-06-11 湖北济生医药有限公司 一种兰索拉唑化合物及其药物组合物
CN104958276A (zh) * 2015-07-30 2015-10-07 青岛蓝盛洋医药生物科技有限责任公司 一种治疗胃溃疡的药物兰索拉唑组合物胶囊
CN105399728B (zh) * 2015-12-20 2017-11-28 寿光富康制药有限公司 一种适用于工业化生产的右兰索拉唑的处理方法
CN106279107A (zh) * 2016-08-10 2017-01-04 成都尚药科技有限公司 一种右旋兰索拉唑晶型的制备方法
CN106749182A (zh) * 2016-11-08 2017-05-31 山东裕欣药业有限公司 一种右旋兰索拉唑晶型化合物及其制备方法
IT201700050223A1 (it) 2017-05-09 2018-11-09 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo cristallino
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880289A (en) * 1996-09-19 1999-03-09 Konica Corporation Crystallization method

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
DK171989B1 (da) * 1987-08-04 1997-09-08 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af 2-(2-pyridylmethylsulfinyl)-benzimidazoler
SE504459C2 (sv) 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
HRP960232A2 (en) 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
JP3828648B2 (ja) 1996-11-14 2006-10-04 武田薬品工業株式会社 ２−（２−ピリジルメチルスルフィニル）ベンズイミダゾール系化合物の結晶およびその製造法
TW385306B (en) * 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
TR199901101T2 (tr) * 1996-11-22 1999-07-21 The Procter & Gamble Company Gastroenstentinal hastaliklarin tedavisine yönelik bizmut ve nsaid içeren bilesimler.
WO1999038512A1 (en) * 1998-01-30 1999-08-05 Sepracor Inc. S-lansoprazole compositions and methods
TWI275587B (en) * 1999-06-17 2007-03-11 Takeda Chemical Industries Ltd A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
JP4536905B2 (ja) * 1999-06-17 2010-09-01 武田薬品工業株式会社 ベンズイミダゾール化合物の結晶
JP3283252B2 (ja) * 1999-06-17 2002-05-20 武田薬品工業株式会社 ベンズイミダゾール化合物の結晶
PT1191025E (pt) * 1999-06-30 2005-09-30 Takeda Pharmaceutical Cristais de lansoprazol
JP2001039975A (ja) * 1999-07-26 2001-02-13 Eisai Co Ltd スルホキシド誘導体の結晶およびその製造法
WO2001014366A1 (fr) 1999-08-25 2001-03-01 Takeda Chemical Industries, Ltd. Procede de preparation de derives optiquement actifs de sulfoxyde
CN1193024C (zh) 2000-04-28 2005-03-16 武田药品工业株式会社 生产旋光的亚砜衍生物的方法
EP1293507B1 (en) 2000-05-15 2007-11-28 Takeda Pharmaceutical Company Limited Process for producing crystal
CN1117747C (zh) * 2000-06-19 2003-08-13 中国科学院成都有机化学研究所 光学纯兰索拉唑的制备方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880289A (en) * 1996-09-19 1999-03-09 Konica Corporation Crystallization method

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012001705A2 (en) 2010-06-29 2012-01-05 Cadila Healthcare Limited Pharmaceutical compositions of (r)-lansoprazole
US9920196B2 (en) 2013-06-20 2018-03-20 Japan Polypropylene Corporation Propylene-based block copolymer
CN104997739A (zh) * 2015-08-31 2015-10-28 青岛蓝盛洋医药生物科技有限责任公司 一种治疗消化系统疾病的药物兰索拉唑组合物冻干粉针剂

Also Published As

Publication number Publication date
DK1337525T3 (da) 2011-09-19
EP1337525B8 (en) 2011-10-05
KR100887912B1 (ko) 2009-03-12
EP1337525B1 (en) 2011-06-01
HK1054380A1 (en) 2003-11-28
PL399787A1 (pl) 2012-11-05
ES2367419T3 (es) 2011-11-03
PL214684B1 (pl) 2013-09-30
HK1054380B (en) 2012-01-27
NO20032437L (no) 2003-07-17
KR20090003348A (ko) 2009-01-09
HUP0400781A3 (en) 2010-03-29
HU229356B1 (en) 2013-11-28
KR20030060967A (ko) 2003-07-16
KR100939948B1 (ko) 2010-02-04
PL362801A1 (en) 2004-11-02
TWI290922B (en) 2007-12-11
ATE511508T1 (de) 2011-06-15
CA2436825C (en) 2011-01-18
WO2002044167A1 (en) 2002-06-06
CY1112347T1 (el) 2015-12-09
EP1337525A1 (en) 2003-08-27
NO326019B1 (no) 2008-09-01
AU2002218506A1 (en) 2002-06-11
PT1337525E (pt) 2011-09-01
US7285668B2 (en) 2007-10-23
EP2345650A1 (en) 2011-07-20
CA2436825A1 (en) 2002-06-06
KR20100002278A (ko) 2010-01-06
US20040049045A1 (en) 2004-03-11
CN1478086A (zh) 2004-02-25
HUP0400781A2 (hu) 2004-07-28
CN1254473C (zh) 2006-05-03
PL409463A1 (pl) 2016-02-15
NO20032437D0 (no) 2003-05-28

Similar Documents

Publication Publication Date Title
US7285668B2 (en) Process for the crystallization of (R)- or (S)-lansoprazole
US9145389B2 (en) Benzimidazole compound crystal
CA2417311C (en) Crystalline alkali metal salts of lansoprazole and their production and use
US7189744B2 (en) Crystals of benzimidazole compounds
US8222422B2 (en) Crystal of benzimidazole compound
JP4160293B2 (ja) 結晶の製造法
HK1159110A (en) Amorphous (r)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1h-benzimidazole as anti-ulcer agent
HK1159634A (en) Amorphous(r)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1h-benzimidazole as anti-ulcer agent
HK1038227B (en) Crystalline form of (r)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1h-benzimidazole

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION